Aerie Pharmaceuticals announces acceptance for review of the Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% marketing authorisation application in Europe

Aerie Pharmaceuticals

2 January 2020 - Aerie Pharmaceuticals today announced that the EMA has accepted for review the marketing authorisation application for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. 

Roclanda is currently marketed as Rocklatan in the United States, where it is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. 

An opinion from the EMA’s Committee for Medicinal Products for Human Use on the application for Roclanda is expected in late 2020.

Read Aerie Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder